Benchling

How do you build an #AI-driven biotech? Our CEO Sajith Wickramasekara will share insights at Decoding Bio's AI x Bio Summit, together with Nabiha Saklayen (CEO, Cellino), Michael Nally (CEO, Generate:Biomedicines), and moderator Bigyan Bista (Enveda Biosciences). Ahead of next week’s event, check out Saji’s op-ed in STAT on the pitfalls and potential of AI in biotech: https://lnkd.in/gFF-ingB

What happens when over 1,500 scientists at Sanofi transition from legacy systems to Benchling? Real-time visibility into standardized data across teams is a critical starting point for their #ML models. See how more than 30 global teams at Sanofi are accelerating R&D with Benchling — from early discovery-omics such as precision oncology, to core therapeutic pipeline teams including novel modalities like mRNA, and all the way up the lifecycle to translational teams. https://lnkd.in/gamMp_yi #PoweredByAI #BuiltOnBenchling

What are 4 of the biggest cloud computing myths in #pharma and life sciences? Benchling’s CISO Zach Powers breaks it down: 🚫 Myth #1: Cloud computing isn’t as safe 🚫 Myth #2: Security is solely the responsibility of the vendor 🚫 Myth #3: As more companies move to cloud, there will be more security incidents 🚫 Myth #4: You can’t verify what’s happening with your data in the cloud In TechInformed, find out why these commonly held — and erroneous — security concerns are holding the pharma industry back: https://lnkd.in/eQGQs-g6

“The focus for #AI can't just be on discovery.” Find out why the rest of the R&D system — developing, testing, approving, and manufacturing drugs — will need to accommodate the imminent increase in speed and scale. https://lnkd.in/ez---fvj

Billions of dollars in funding may not be enough. What happens when #AI fuels more drug candidates than our current R&D system can handle? ICYMI: Benchling CEO Sajith Wickramasekara joined industry experts at #FTPharma to weigh in — how will #biopharma need to adapt R&D processes and teams to make the most of AI/ML? https://lnkd.in/eSTGFY7g

With over 1,600 drug candidates in preclinical and clinical development, RNA-based therapeutics are on the rise. But modeling siRNA and oligonucleotide conjugates can be challenging — until now. Find out how you can now design and visualize siRNAs and antisense oligonucleotide conjugates directly in Benchling: https://lnkd.in/eME6Mmtr

🍎 Attention all Benchling users in NYC! We’re excited to launch a Benchling User Group in your area! These groups are led by Benchling users, for Benchling users. Whether you’re a scientist, admin, developer, or data scientist, come connect with your colleagues and share your ideas, solutions, and tips. Join the online group and connect with NYC’s group leader Ada Zhang — stay tuned for more info on the first local meetup! https://lnkd.in/eeN__hjX #BenchlingCommunity

Pharma R&D has a known efficiency challenge. Today’s companies spend upwards of $6 billion in R&D per drug approval. So how do we turn it around? Benchling co-founders Sajith Wickramasekara and Ashu Singhal discuss how the industry must use #AI and technology to confront inefficiencies across the entire R&D lifecycle, especially as the scale and speed of AI-discovered drugs pressures the system to bring more treatments to market, faster. https://lnkd.in/eKGQhR3u

In La Tribune, see how European biopharma, including Sanofi, are using Benchling to centralize and unify their R&D data, enabling collaboration and the implementation of #AI. Find out how we’re putting the cloud at the service of biotechs in France and around the world. 🇫🇷 En français: https://lnkd.in/eKixuRfV

See how the development teams at Zealand Pharma ensure real-time access to data and secure information exchange with multiple CMO partners — all on a GxP-compliant platform. https://lnkd.in/eyzKhg95 #BuiltOnBenchling